High‐dose rabeprazole–amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2012-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2036.2012.05054.xPMID 22404486
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Letter: the ethics of using inferior regimens in H. pylori randomised trials

  2012cited by this paper
• Letter: the ethics of using inferior regimens in H. pylori randomised trials – editors’ reply

  2012cited by this paper
• High Helicobacter pylori Resistance to Metronidazole but Zero or Low Resistance to Clarithromycin, Levofloxacin, and Other Antibiotics in Malaysia

  2011cited by this paper
• Clarithromycin resistance and point mutations in the 23S rRNA gene in Helicobacter pylori isolates from Malaysia

  2010cited by this paper
• Efficacy of 1‐week proton pump inhibitor triple therapy as first‐line Helicobacter pylori eradication regime in Asian patients: Is it still effective 10 years on?

  2010cited by this paper
• Helicobacter pylori treatment in the era of increasing antibiotic resistance

  2010cited by this paper
• Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice.

  2010cited by this paper
• Second Asia–Pacific Consensus Guidelines for Helicobacter pylori infection

  2009cited by this paper
• Prevalence of Primary Fluoroquinolone Resistance Among Clinical Isolates of Helicobacter pylori at a University Hospital in Southern Taiwan

  2009cited by this paper
• Rabeprazole

  2009cited by this paper
• A Report on the International Transglutaminase Autoantibody Workshop for Celiac Disease

  2008cited by this paper
• Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility.

  2007cited by this paper
• Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy

  2007cited by this paper
• Systematic review and meta‐analysis: levofloxacin‐based rescue regimens after Helicobacter pylori treatment failure

  2006cited by this paper
• Third-Line Rescue Therapy with Levofloxacin After Two H. pylori Treatment Failures

  2006cited by this paper
• Randomized trial of rifabutin‐based triple therapy and high‐dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin

  2006cited by this paper
• Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

  2006cited by this paper
• Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients.

  2005cited by this paper
• Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status

  2004cited by this paper
• H pylori antibiotic resistance: prevalence, importance, and advances in testing

  2004cited by this paper
• High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.

  2003cited by this paper
• Retreatment of H. pylori with dual therapy using high doses of rabeprazole or lansoprazole can be effective

  2003cited by this paper
• High rate of post‐therapeutic resistance after failure of macrolide–nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second‐line therapies in a randomized study

  2002cited by this paper
• Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.

  2001cited by this paper
• Efficacy of short‐course lansoprazole with clarithromycin and amoxicillin in the eradication of Helicobacter pylori in South‐East Asian patients: 5‐day t.d.s. versus 7‐day b.d. treatment regimens

  2001cited by this paper
• Efficacy of a 1‐week pantoprazole triple therapy in eradicating Helicobacter pylori in Asian patients

  2000cited by this paper
• High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong

  2000cited by this paper
• Triple Versus Dual Therapy for Eradicating Helicobacter pylori and Preventing Ulcer Recurrence: A Randomized, Double-Blind, Multicenter Study of Lansoprazole, Clarithromycin, and/or Amoxicillin in Different Dosing Regimens

  1998cited by this paper
• Management of Helicobacter pylori infection--a Working Party Report of the Malaysian Society of Gastroenterology and Hepatology.

  1998cited by this paper
• An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively

  1997cited by this paper
• Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.

  1997cited by this paper
• Combination amoxycillin and metronidazole with famotidine in the eradication of Helicobacter pylori—a randomized, double‐blind comparison of a three times daily and twice daily regimen

  1997cited by this paper
• Dual therapy with high or low doses of omeprazole does not achieve an acceptable rate of Helicobacter pylori eradication in duodenal ulcer patients. A multicentre randomized long-term detailed study.

  1997cited by this paper
• Comparison of two 1‐week low‐dose omeprazole triple therapies— optimal treatment for Helicobacter pylori infection?

  1997cited by this paper
• High‐dose proton pump inhibitor plus amoxycillin for the treatment or retreatment of Helicobacter pylori infection

  1996cited by this paper
• Double‐Blind, Multicenter Evaluation of Lansoprazole and Amoxicillin Dual Therapy for the Cure of Helicobacter pylori Infection

  1996cited by this paper
• Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers.

  1995cited by this paper
• Low dose clarithromycin plus omeprazole eradicates Helicobacter pylori in duodenal ulcer disease.

  1995cited by this paper
• Primary and acquired Clarithromycin resistance amongst Helicobacter pylori strains in Malaysia.

  1995cited by this paper
• An increasing dose of omeprazole combined with amoxicillin improves the cure of Helicobacter pylori infection

  1995cited by this paper
• Primary and acquired resistance to clarithromycin among Helicobacter pylori strains in Malaysia.

  1995cited by this paper
• Acute colonic ulceration proximal to obstructing colon neoplasms.

  1992cited by this paper
• Metronidazole resistance among Helicobacter pylori strains in Malaysia.

  1992cited by this paper
• High dose omeprazole treatment combined with amoxicillin eradicates Helicobacter pylori

  1992cited by this paper
• Effect of varying pH on the susceptibility ofCampylobacter pylori to antimicrobial agents

  1989cited by this paper

• Traditional Strategies and Cutting-Edge Technologies Used for Plant Disease Management: A Comprehensive Overview

  2024cites this paper
• A Malaysian consensus report on the diagnosis and treatment of Helicobacter pylori infection

  2023cites this paper
• 14-day pantoprazole- and amoxicillin-containing high-dose dual therapy for Helicobacter pylori eradication in elderly patients: A prospective, randomized controlled trial

  2023cites this paper
• Dual therapy for Helicobacter pylori infection

  2023cites this paper
• Which is the best choice for Helicobacter pylori eradication? Dual therapy or quadruple therapy?

  2022cites this paper
• Sex-Specific Risk Factors Associated with Helicobacter pylori Infection Among Individuals Undergoing Health Examinations in China

  2022cites this paper
• Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth‐containing quadruple therapy for Helicobacter pylori eradication in central China: A single‐center, prospective, open‐label, randomized‐controlled trial

  2022cites this paper
• Current status of Helicobacter pylori resistance to Clarithromycin and Levofloxacin in Malaysia—findings from a molecular based study

  2021cites this paper
• High‐dose dual therapy and CYP2C19 polymorphism in Helicobacter pylori eradication

  2021cites this paper
• Update on quinolone-containing rescue therapies for Helicobacter pylori infection

  2020cites this paper
• High‐dose proton pump inhibitor and amoxicillin dual therapy with or without bismuth for 14 days as rescue therapies after Helicobacter pylori treatment failure

  2020cites this paper
• A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.

  2019cites this paper
• High Prevalence of Antibiotic Resistance in Iranian Helicobacter pylori Isolates: Importance of Functional and Mutational Analysis of Resistance Genes and Virulence Genotyping

  2019cites this paper
• High prevalence of antibiotic resistance in Helicobacter pylori isolates from Iran: importance of functional and mutational analysis of resistance genes and virulence genotyping

  2019cites this paper
• Helicobacter Pylori - a Worldwide Perspective 2014

  2018cites this paper
• Systematic review, meta‐analysis, and meta‐regression: Successful second‐line treatment for Helicobacter pylori

  2018cites this paper
• Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Salvage Therapy in the USA: A Real Life Experience

  2018cites this paper
• Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance

  2017cites this paper
• Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.

  2016cites this paper
• Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study

  2016cites this paper
• Treatment of Helicobacter pylori infection: Current and future insights.

  2016cites this paper
• Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy.

  2015cites this paper
• Functional and Molecular Surveillance of Helicobacter pylori Antibiotic Resistance in Kuala Lumpur

  2014cites this paper
• Efficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies

  2014cites this paper
• Treatment of Helicobacter pylori infection: current status and future concepts.

  2014cites this paper
• Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis

  2014cites this paper
• Prevalence of Helicobacter pylori Infection and its Relation with Body Mass Index in a Chinese Population

  2014cites this paper
• Rabeprazole-Based Rescue Therapy for Helicobacter pylori Successful in Malaysia

  2012cites this paper
• Letter: third‐line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection – author's reply

  2012cites this paper
• Letter: rising incidence of obesity in the coeliac population – a malady or maladaptation? Authors' reply

  2012cites this paper
• Letter: third‐line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection

  2012cites this paper
• Treatment of Helicobacter pylori infection 2012

  2012cites this paper